Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer

Soo Youn Bae, Seok Jin Nam, Yongsik Jung, Sae Byul Lee, Byung Woo Park, Woosung Lim, Sung Hoo Jung, Hsien Wen Yang, Seung Pil Jung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. Methods: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients. Results: In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy. Conclusion: The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.

Original languageEnglish
JournalBreast Cancer Research and Treatment
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Triple Negative Breast Neoplasms
Drug Therapy
Breast Neoplasms

Keywords

  • Chemotherapy
  • Immunohistochemistry
  • P53
  • Prognosis
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. / Bae, Soo Youn; Nam, Seok Jin; Jung, Yongsik; Lee, Sae Byul; Park, Byung Woo; Lim, Woosung; Jung, Sung Hoo; Yang, Hsien Wen; Jung, Seung Pil.

In: Breast Cancer Research and Treatment, 01.01.2018.

Research output: Contribution to journalArticle

Bae, Soo Youn ; Nam, Seok Jin ; Jung, Yongsik ; Lee, Sae Byul ; Park, Byung Woo ; Lim, Woosung ; Jung, Sung Hoo ; Yang, Hsien Wen ; Jung, Seung Pil. / Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. In: Breast Cancer Research and Treatment. 2018.
@article{481d36085c6f4d5ab8cbfd3d7ae0d8aa,
title = "Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer",
abstract = "Purpose: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. Methods: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients. Results: In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy. Conclusion: The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.",
keywords = "Chemotherapy, Immunohistochemistry, P53, Prognosis, Triple-negative breast cancer",
author = "Bae, {Soo Youn} and Nam, {Seok Jin} and Yongsik Jung and Lee, {Sae Byul} and Park, {Byung Woo} and Woosung Lim and Jung, {Sung Hoo} and Yang, {Hsien Wen} and Jung, {Seung Pil}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10549-018-4928-2",
language = "English",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer

AU - Bae, Soo Youn

AU - Nam, Seok Jin

AU - Jung, Yongsik

AU - Lee, Sae Byul

AU - Park, Byung Woo

AU - Lim, Woosung

AU - Jung, Sung Hoo

AU - Yang, Hsien Wen

AU - Jung, Seung Pil

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. Methods: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients. Results: In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy. Conclusion: The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.

AB - Purpose: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. Methods: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients. Results: In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy. Conclusion: The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.

KW - Chemotherapy

KW - Immunohistochemistry

KW - P53

KW - Prognosis

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85052092591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052092591&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4928-2

DO - 10.1007/s10549-018-4928-2

M3 - Article

C2 - 30132220

AN - SCOPUS:85052092591

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -